HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Current strategies in whole-brain radiation therapy for brain metastases.

Abstract
Whole-brain radiation therapy (WBRT) has been the primary treatment for patients with brain metastases for more than 50 years and provides effective palliative relief in most patients. Although advancements in radiotherapeutic technique continue to improve local and locoregional control, median survival for patients treated with WBRT monotherapy remains fixed at approximately 4 to 6 months. Key issues in the use of WBRT include optimizing its efficacy when it is used in conjunction with surgery, radiosurgery, radiosensitizers, and new chemotherapeutic agents. These multimodal approaches to brain metastases have resulted in significant increases in the median survival time in many patients. Radiosurgery is part of a continuing effort to improve the effects of radiation therapy, especially in brain metastases. The optimal combination of WBRT and radiosurgery remains to be elucidated, including appropriate timing or sequence and use in conjunction with other modalities. Newer radiosensitizing agents (e.g., efaproxiral [RSR-13] and motexafin gadolinium) have shown promise in the treatment of brain tumors, especially in specific patient subsets. Recently developed systemic chemotherapy agents, such as temozolomide, which crosses the blood-brain barrier, have a synergistic effect on brain metastases when used in conjunction with radiation. In addition, the use of interstitial chemotherapy agents provides highly focused local chemotherapy in the brain without increasing systemic toxicity; carmustine polymer wafer, in combination with WBRT, has shown promising results in treating brain metastases.
AuthorsMinesh P Mehta, Deepak Khuntia
JournalNeurosurgery (Neurosurgery) Vol. 57 Issue 5 Suppl Pg. S33-44; discusssion S1-4 (Nov 2005) ISSN: 1524-4040 [Electronic] United States
PMID16237287 (Publication Type: Comparative Study, Journal Article, Review)
Chemical References
  • Biocompatible Materials
  • Decanoic Acids
  • Drug Carriers
  • Polyesters
  • Radiation-Sensitizing Agents
  • decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer
Topics
  • Biocompatible Materials
  • Brachytherapy
  • Brain Neoplasms (drug therapy, radiotherapy, secondary, surgery)
  • Cranial Irradiation (adverse effects, methods, trends)
  • Decanoic Acids
  • Dose Fractionation
  • Drug Carriers
  • Humans
  • Neurosurgical Procedures
  • Polyesters
  • Radiation-Sensitizing Agents (therapeutic use)
  • Radiosurgery

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: